Most patients needing intensive care cannot give informed consent to participation in research. This includes the most acutely and severely ill, with the highest mortality and morbidity where research has the greatest potential to improve patient outcomes. In these circumstances consent is usually sought from a substitute decision maker, but while survivors of intensive care believe substitute decision makers will look after their interests, evidence suggests substitute decision makers are poorly equipped for this task. Various models have been suggested for research without patient informed consent when intervention is urgent and cannot wait until first person consent is possible, including a waiver of consent if conditions are met. A nationally consistent model is proposed for Australia with a robust process for initial waiver of consent followed by first person consent to further research-related procedures or ongoing follow-up when this can be competently provided.
Most patients who need intensive care do not have the capacity to provide informed consent to participate in research. Even if patients are not sedated and mechanically ventilated, they are likely to need analgesia or, alternatively, the effects of their illness, delirium and organ failure will limit the ability to comprehend and make an informed decision about a research study explained in an informed consent document that can be ten pages or more.
These issues are not unique to intensive care. Other patient groups including those with dementia, other cognitive impairment, significant psychiatric illness, young children and patients undergoing cardiopulmonary resuscitation, for example, lack the competence to provide informed consent for research. Even in the context of acute myocardial infarction where our treatment is guided by numerous large clinical trials, the quality of informed consent has been questioned 1 .
In most intensive care units a proportion of patients are admitted after elective procedures. This provides the opportunity to obtain prospective informed consent for research and is used for studies relating to surgical intervention, anaesthesia and postoperative care. But these patients form a relatively low morbidity and mortality population in intensive care. Results from this patient population cannot necessarily be extrapolated to other patients needing intensive care. Those patients with the highest morbidity and mortality are typically acutely, unexpectedly and severely ill or have been subject to major trauma and are incompetent to provide informed consent. It is here that research has the greatest potential to reduce morbidity, mortality and the costs of healthcare.
In Australia, research is governed by the National Statement on Ethical Conduct in Human Research 2007 (updated March 2014) 2 . The Statement emphasises the need to provide for the protection of those with diminished or no autonomy, defined as the capacity to determine one's own life and make one's own decisions. It also acknowledges that research into the interventions and treatments (needed by people who are highly dependent on medical care but unable to give consent) is necessary to assess and improve their efficiency.
The process is set out in some detail, but is subject to 'relevant jurisdictional laws', specifically in relation to the consent process where this can be given by the participant's guardian or persons or organisations authorised by law. Unfortunately, Australia does not have uniform legislation relating to such authority. There are also provisions for a Human Research Ethics Committee to approve a research project, including interventional research, without prior patient consent. For interventional research there needs to be a possibility of benefit over standard care, a justifiable balance of risk to potential benefit and it must not be contrary to the interests of a participant.
Little is known about the consent process preferences of critically ill patients and it is likely that there are cultural and geographic variations. A Canadian study that used structured interviews and theoretical scenarios 3 in 240 survivors of intensive care found over three-quarters preferred prospective consent by a substitute decision maker (SDM) before study enrolment, to delayed consent by a SDM or delayed consent from the patient. Only 6% supported no formal consent process. Interestingly, these proportions changed little with the potential risk of the intervention or comparison of two currently available treatments. A weakness of the study is the theoretical nature of the scenarios, but it is nevertheless a reflection of patients' belief that SDMs will look after their interests and support their wishes.
However, the ability of SDMs to reflect an individual patient's decisions in relation to medical treatment or research is poor 4 . Many SDMs are being confronted with complex and life-threatening illness in a loved one for the first time, in a situation where treatment must be given quickly to maximise its benefit. Often there is little time for the SDM to be fully educated about the nature of the disease, treatment options, potential complications and prognosis, even without the additional burden of understanding the nature and implications of a research project or clinical trial. A focus group-based study of SDMs' perspectives on critical illness research 5 reported many found the SDM role overwhelming or stressful. Some assumed that being approached to participate in research implied their loved one's situation was dire and non-participation may represent a lost opportunity for successful treatment. Reluctance to actively participate as a SDM is exacerbated by the frequency of 'learned helplessness' which affects over half of the family members of intensive care unit patients 6 . This is consistent with the findings of a questionnaire study of SDMs 7 which found the most common reason for declining consent (67%) was that the SDM was too anxious to consider research. The most common reasons for agreeing to research were the potential for research to help others (91%) and that research is important for medical progress (88%)-essentially altruistic reasons not related to the individual patientthough many also believed that participation would help their loved one recover faster.
An Australian study 8 of families of patients in intensive care and emergency departments found only 17% strongly agreed to research if they were critically ill and consent by SDMs was acceptable to only 26% of participants. Issues relating to the legal status of SDM consent have been raised in Western Australia because of the requirement that SDMs act in the 'patient's best interests'. What exactly this means is unclear because it has not been tested by a court within the jurisdiction. On the one hand, it could mean that interventional research or even observational research is not possible because there is no certainty of benefit to the participant and there may be a risk of harm, however small. Similar considerations may apply to SDM consent for procedures relating to organ donation after cardiac death, though again this has not been tested. On the other hand, while some have pointed to evidence that the outcomes for participants in research are better than for those who do not, a recent systematic review found that, at worst, study participants do not suffer clinically important harm 9 . Therefore, participation in research cannot be argued to be against the 'patient's best interests'.
Given all these issues with SDM consent and the usual inability of participants to give informed consent themselves, it is not surprising that other processes have been invoked (Table 1) 10 . All have their strengths and weaknesses. For example, the deferred consent models may lead to selection bias unless the confirmed consent rate is very high and there needs to be an alternative process for early deaths that prevent patients having the opportunity to give consent. Deferred SDM consent overcomes issues related to time pressure, but not the other issues related to SDM consent. Some will question the true independence of authorised representatives and the opt-out nature of objection to participation also raises questions as to whether the interests of potential research participants are really being protected. Even within landmark clinical trials varying models of consent to participation have occurred. For example, the Saline versus Albumin Fluid Evaluation (SAFE) study comparing albumin and saline for fluid resuscitation used varying forms of deferred consent 11 and the Normoglycemia in Intensive Care Evaluation and Surviving Using Glucose Algorithm Regulation (NICE-SUGAR) trial comparing tight Table 1 Alternative models for consent to participation in research for critically ill patients (modified from 10).
Alternative model for consent

Deferred patient consent
Patient is enrolled with the intent of obtaining consent when the patient is competent. SDM and family usually informed of inclusion and the study.
Deferred SDM consent Patient is enrolled with the intent of obtaining SDM consent at the earliest opportunity.
Authorised representative consent Patient is enrolled after two independent physicians, neither involved in the research, consent on the patient's behalf.
Objection to participation
Patient is enrolled if the SDM indicates the patient would not 'object to participation' (rather than agreeing to participation).
Waived consent
The HREC determines that the requirement for consent can be waived.
SDM=surrogate decision maker, HREC=Human Research Ethics Committee, 10=reference no. 10. and more permissive glycaemic control used varying forms of deferred consent in Australia and New Zealand but prospective consent from a SDM in Canada 12 .
Going back to first principles, in 1978 the United States National Commission for the Protection of Human Subjects in Biomedical and Behavioural Research 13 listed three basic principles for research involving human subjects: respect for persons, beneficence and justice. Respect for persons underpins the principle of first person consent to research, when this is possible. When it is not possible, other elements of study design become more important such as confidentiality and respect for the privacy of the participant, the provision of easy-to-understand information about the research to participants' families and the participant when they are competent to understand, consent to any ongoing study-related procedures by the participant when they are competent, and elements of study design including true equipoise regarding risk and benefit in interventional studies and ensuring 'toxic placebos' and control arms that do not reflect a true standard of care are avoided. The research should also have a realistic prospect of providing clinically useful outcomes based on available evidence. These principles are largely included in the US Food and Drug Administration guidelines for conducting research without informed consent, also known as the 'final rule' 14 .
The principle of beneficence is served by positive outcomes for the community from the research and justice by ensuring that all patients in centres undertaking the research who meet the inclusion criteria have an equal opportunity to participate.
In Australia, I would argue that the community can be best served by a model for undertaking research without patient consent in incompetent patients that is nationally consistent and the principle of justice should require patients to have the same chance of participation regardless of the state or territory in which they live. I would argue for a robust model of waiver of consent until the participant is able to consent to participation in ongoing study-related activities. Such a model would overcome the issues identified in relation to consent from SDMs and reduce any additional stress on SDMs when they are often under extreme pressure from unexpected critical illness in a loved one. It is also likely to increase the rate of enrolment 15 and in doing so, reduce a source of bias and increase the probability that studies will be completed, consistent with the ethical principle of beneficence.
Research proposals could be considered by a state-based or national committee with strong representation by members with expertise in the design of research studies and clinical trials, data security and community representatives. Such a committee could report to the Australian Health Ethics Committee as well as individual site Human Research Ethics Committees where the research is to be carried out. Information is lacking on the Australian community's potential response to this approach, but an evaluation in the US of community consultations on using exception from informed consent found 88% supported a clinical trial of anticonvulsants given without consent being carried out in their community 16 . Acceptance of a waiver of informed consent among actual study participants may be even higher, based on interviews with participants in a clinical trial in patients with traumatic brain injury 17 . Community support for interventional clinical trials without first person consent might be further increased by using response adaptive randomisation 18 in which the ratio of participants assigned to each arm of the trial is adjusted based on patient outcomes while the study continues, based on a predefined set of rules so that patients have a greater chance of receiving the more effective treatment.
Intensive care research with a waiver of consent was considered by many in the intensive care community as a means of improving care and patient outcomes when faced with the H1N1 pandemic. While this subsided, the epidemics of severe trauma, septic shock, cardiac arrest and others continue. There seems no ethical reason to apply different principles dependent on the disease process. Individual patient rights and the balance of risk and benefit to which they are exposed must be safeguarded, but when patients are unable to provide consent this can be balanced against the considerations of risk and benefit for the community as a whole.
